Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. The company offers serratiopeptidase, fungal lactase, peptizyme SP, nattokinase, fungal lipase, alpha galactosidase, saccharomyces boulardii, hemicellulose, papain, bromelain,...
Advanced Enzyme Technologies reported revenue of 7.46 billion INR for fiscal year 2026, up 17.2% from fiscal year 2025, and net income of 1.69 billion INR. India was its largest region in fiscal year 2025, with 46% of revenue. Its market capitalization was 29.44 billion INR as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2026; market data as of October 9, 2026.
No profile data available.